Nivolumab vs Sorivudine
Nivolumab vs Sorivudine: Overview
This comparison examines the pharmacological differences between Nivolumab and Sorivudine.
Mechanism of Action
Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.
Pharmacokinetics
Half-life: Nivolumab — 27 days.
Chemical Properties
Type: Nivolumab — Antibody; Sorivudine — Small molecule.